Statement

S.No.	Name of the Product	Pack Size	Earlier Price	Current Price	%age increase
1	2	3	4	5	6
1	Fersolate Tablets 500 Mcg	500's	12.56	25.37	102 0
2	Macrabin Injection	5x5ml	3.90	6 00	53 8
3	Macrabin Injection	5x5ml	4.71	7 85	66 7
4	Dilosyn Tablets	250's	1.39	2 51	80 6
5	Dilosyn Syrup	120ml	6.04	10.44	72 8
6	Dilsoyn Expt.	120ml	5 03	9 53	89 5
7	Do.	450ml	13.61	27 74	103 8
8	Kapilin Injection	6x1ml	5 19	12 00	131 2
9	Vitamin E Caps	100's	21 06	40 00	89 9
10	Benadryl Syrup	114ml Bottle	6.04	7 36	21 1
11	Do.	460ml Bottle	19.30	22.51	16 6
12	Benadryl Caps. 25mg.	100 Strip	2.18	2.55	17 0
13	Do.	100'sx Bottle	16.90	19 73	16 8
14	Benadryl Expt.	114ml Bottle	6.36	9 00	52 8
15	Do.	456ml Bottle	18 55	24 02	29 5
16	Caladryl Lotion	171ml Bottle	7 59	11 00	44 9
17	Sudafed Tablets	10's Strip	3.46	4 39	26 9
18	Sudafed Syrup	115ml Bottle	11.37	13 17	15 8
19	Do.	455ml Bottle	23.90	37 06	55 1

Prices of Livogen etc.

666. SHRI VITHALRAO MADHAVRAO JADHAV: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the prices of Iron salt preparations have gone up substantially due to the recent Drugs Price Control Order;

(b) what was the price of Livogen, Raricap, Plastules, Autrin, Dumasules Fefol Hemfer, Heamup, Rarical, Heptaglobine, Rubraplex and Dexorange before the announcement of DPCO, 1987 and what is the present prices of each drug;

(c) whether it is a fact that Government had announced that in case of increase in prices, the medicines would be brought back under price control; and

(d) if so, what action has been taken in this regard?

THE MINISTER OF STATE IN THE DEPARTMENT OF INDUSTRIAL DEVELOPMENT IN THE MINISTRY OF INDUSTRY (SHRI M. ARUNACHALAM): (a) Prices of single ingredient iron preparations or those in combination with non-scheduled bulk drugs have gone up.

(b) All the products referred to in the question except Heptaglobine are price controlled under DPCO, 1987. The Govern-

ment have not so far revised their prices as per DPCO, 1987.

(c) and (d) As per provisions of DPCO, 1987, the Government is empowered to bring any of the non-scheduled drugs within the ambit of control, if it is considered necessary to do so.

Panel for Assistant Accounts Officers in SECL

667. SHRI DHARAM CHANDER PRASHANT: Will the Minister of ENERGY be pleased to state:

(a) whether it is fact that South Eastern Coalfieds Ltd., had prepared a panel of those Accountants possessing CA (Inter)| ICWA(Inter) qualification with more than one year's service in that company for promotion to the next higher grade of Assistant Account Officer;

(b) whether it is also a fact that such a panel prepared for promotion to the next higher grade of AAO has already been enforced in other subsidiary companies of Coal India Ltd.;

(c) if so, by when the said panel will be enforced by SECL; and

(d) what are the reasons for the delay in implementing the panel by SECL?

THE MINISTER OF STATE IN THE DEPARTMENT OF COAL IN THE MINISTRY OF ENERGY (SHRI C. K. JAFFAR SHARIEF): (a) The Board of SECL had decided in May, 1987 that is the first instance, Accountants who had passed CA Inter|ICWA Inter and had minimum of 3 years service should be considered for promotion to the post of Asstt. Accounts officer. The company is now, preparing a panel of Accountants possessing these qualifications irrespective of the length of service.

(b) Panels have already been formed in ECL, BCCL, WCL, NCL and CMPDIL.

(c) and (d) Do not arise, since the panel is still to be finalised. After the panel has been finalised promotion will be made depending on the availability of vacancies.

Antah Gas Power Project

668. SHRI BHUVNESH CHATURVEDI: Will the Minister of ENERGY be pleased to state:

(a) whether there is any proposal to double the capacity of Antah Gas Power Project at Antah in Rajasthan in view of the surplus gas available there; and

(b) if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF POWER IN THE MINISTRY OF ENERGY (SHRIMATI SUSHILA ROHATGI): (a) There is no such proposal at present.

(b) Does not arise.

Sales turn-over at Dexorange etc.

669. SHRI VITHALRAO MADHAVRAO JADHAV: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that sales turnover of Dexorange was Rs. 1144.60 lakhs, Rubraplex 168.51 lakhs, Heptaglobine 551.61 lakhs, Rarical 139.40 lakhs, Tonofarron 201.21 lakhs, Heamup 220.21 lakhs, Remful 257.62 lakhs, Fefol 425 lakhs, Dumasules 108.20 lakhs Autrin 188.39 lakhs, Raricap 209.08 lakhs and Livogen 248.07 lakhs during 1986; and

(b) if so, what is the specific criteria under which each of these medicines was recommended for exemption from price control?

THE MINISTER OF STATE IN THE DEPARTMENT OF INDUSTRIAL DEVELOPMENT IN THE MINISTRY OF INDUSTRY (SHRI M. ARUNACHALAM): (a) Sales turn-over of formuations is not monitored.

(b) To the extent information is available, all the products referred to in the question except Heptaglobine contain Vitamins in combinations and are therefore price controlled under DPCO, 1987. M|s. Raptakos Brett and Co. have reformulated their products Heptoglobin-in-one to exclude the vitamin ingredients and the reformulated product is exempted from price control under DPCO, 1987.